Peptide Therapy

Tirzepatide, sold under the brand name Mounjaro (FDA Approved 2022)

Losing weight can be an incredibly difficult endeavor which can impact your lifestyle. We all know there are no magic pills & nothing works better than time & effort. Bergen Total Health offers medications that are available that can assist with weight loss, fat loss, & even helps control insulin levels. The best part, these medications only have to be administered once a week.

Tirzepatide is the latest weight-loss peptide that, at therapeutic doses, acts on centers in the brain & suppresses appetite. This peptide focuses on both weight AND fat loss by working in two different paths.  Used in conjunction with diet & exercise, Tirzepatide helps patients adhere to a reduced-calorie diet, enhancing the weight loss process. Approved in March 2022 by the FDA, brand name called Mounjaro™,  as an adjunct to diet & exercise to improve glycemic control in adults with type 2 diabetes mellitus, Tirzepatide injection is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor & glucagon-like peptide-1 (GLP-1) receptor agonist.

Tirzepatide has been called Semaglutide 2.0 because patients have lost more weight in the same period of time, felt a heavier suppression of appetite, and showed fewer side effects. This is undoubtedly Semaglutide 2.0 with enhanced upgrades and bug fixes. Tirzepatide demonstrated a greater decrease in HbA1c and weight loss than Semaglutide.

Key Benefits

• Reduces food intake by lowering appetite
• Slows food digestion in the stomach
• Helps decrease body fat percentage & weight loss which is superior to Semaglutide
• Increases energy expenditure resulting in substantial & sustained reductions in body weight
• Decreased cardiovascular outcomes in subjects with type 2 diabetes
• Lower HbA1c levels

Risks

The most common side effects may include: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, gas, & heartburn.